Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 1.02
BCRX's Cash-to-Debt is ranked lower than
81% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. BCRX: 1.02 )
Ranked among companies with meaningful Cash-to-Debt only.
BCRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.02  Med: No Debt Max: No Debt
Current: 1.02
Equity-to-Asset 0.02
BCRX's Equity-to-Asset is ranked lower than
91% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. BCRX: 0.02 )
Ranked among companies with meaningful Equity-to-Asset only.
BCRX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.02  Med: 0.61 Max: 0.97
Current: 0.02
-0.02
0.97
Piotroski F-Score: 2
Altman Z-Score: -6.68
Beneish M-Score: -2.07
WACC vs ROIC
19.93%
-390.12%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -184.45
BCRX's Operating Margin % is ranked lower than
59% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. BCRX: -184.45 )
Ranked among companies with meaningful Operating Margin % only.
BCRX' s Operating Margin % Range Over the Past 10 Years
Min: -336.35  Med: -105.32 Max: -18.42
Current: -184.45
-336.35
-18.42
Net Margin % -209.25
BCRX's Net Margin % is ranked lower than
61% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. BCRX: -209.25 )
Ranked among companies with meaningful Net Margin % only.
BCRX' s Net Margin % Range Over the Past 10 Years
Min: -332.08  Med: -118.9 Max: -18.03
Current: -209.25
-332.08
-18.03
ROE % -291.83
BCRX's ROE % is ranked lower than
94% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. BCRX: -291.83 )
Ranked among companies with meaningful ROE % only.
BCRX' s ROE % Range Over the Past 10 Years
Min: -544.61  Med: -69.75 Max: -20.28
Current: -291.83
-544.61
-20.28
ROA % -56.41
BCRX's ROA % is ranked lower than
71% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. BCRX: -56.41 )
Ranked among companies with meaningful ROA % only.
BCRX' s ROA % Range Over the Past 10 Years
Min: -59.43  Med: -40.93 Max: -11.86
Current: -56.41
-59.43
-11.86
ROC (Joel Greenblatt) % -557.48
BCRX's ROC (Joel Greenblatt) % is ranked lower than
54% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. BCRX: -557.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BCRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -15669.01  Med: -948.36 Max: -202.66
Current: -557.48
-15669.01
-202.66
3-Year Revenue Growth Rate 4.50
BCRX's 3-Year Revenue Growth Rate is ranked lower than
51% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. BCRX: 4.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BCRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -70.7  Med: -3.15 Max: 528
Current: 4.5
-70.7
528
3-Year EBITDA Growth Rate 13.00
BCRX's 3-Year EBITDA Growth Rate is ranked higher than
65% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. BCRX: 13.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BCRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -41.9  Med: -5.7 Max: 63.7
Current: 13
-41.9
63.7
3-Year EPS without NRI Growth Rate 10.90
BCRX's 3-Year EPS without NRI Growth Rate is ranked higher than
64% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. BCRX: 10.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BCRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -38.4  Med: -5.7 Max: 52.9
Current: 10.9
-38.4
52.9
GuruFocus has detected 6 Warning Signs with Biocryst Pharmaceuticals Inc $BCRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BCRX's 10-Y Financials

Financials (Next Earnings Date: 2017-05-04)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

BCRX Guru Trades in Q1 2016

John Paulson 263,100 sh (New)
Chuck Royce 160,000 sh (New)
Paul Tudor Jones 125,588 sh (+1022.83%)
Jim Simons 292,221 sh (+104.49%)
Joel Greenblatt Sold Out
» More
Q2 2016

BCRX Guru Trades in Q2 2016

John Paulson 263,100 sh (unchged)
Chuck Royce 160,000 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones 16,687 sh (-86.71%)
» More
Q3 2016

BCRX Guru Trades in Q3 2016

John Paulson 363,100 sh (+38.01%)
Chuck Royce 160,000 sh (unchged)
Paul Tudor Jones 11,137 sh (-33.26%)
» More
Q4 2016

BCRX Guru Trades in Q4 2016

Jim Simons 49,903 sh (New)
John Paulson 350,000 sh (unchged)
Paul Tudor Jones Sold Out
Chuck Royce 144,000 sh (-10.00%)
John Paulson 52,600 sh (-85.51%)
» More
» Details

Insider Trades

Latest Guru Trades with BCRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:ADAP, NAS:AKBA, NAS:CARA, NAS:PTCT, NAS:ATRA, NAS:WVE, NAS:NTLA, NAS:LJPC, NAS:RARX, NAS:BYSI, NAS:ANAB, NAS:ACIU, NAS:NLNK, NAS:AUPH, NAS:INO, NAS:ACHN, NAS:RETA, NAS:PGNX, OTCPK:ZLDPF, NAS:CERS » details
Traded in other countries:BO1.Germany,
Headquarter Location:USA
Biocryst Pharmaceuticals Inc is a biotechnology company. The Company designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases.

Biocryst Pharmaceuticals is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modelling, and medical chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

Top Ranked Articles about Biocryst Pharmaceuticals Inc

BioCryst to Announce First Quarter 2017 Financial Results May 4
BioCryst Expands Development of BCX7353 to Explore Treatment of Acute HAE Attacks
BioCryst Announces Mundipharma Receives Approval for Mundesine® in Japan
BioCryst Pharmaceuticals Prices Public Offering of Common Stock

RESEARCH TRIANGLE PARK, N.C., March 09, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the pricing of an underwritten public offering of 5,294,118 shares of its common stock, offered at a price to the public of $8.50 per share.  The gross proceeds from this offering to BioCryst are expected to be $45.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by BioCryst.  BioCryst has granted the underwriters a 30-day option to purchase up to an additional 794,117 shares of its common stock.  The offering is expected to close on or about March 15, 2017, subject to customary closing conditions. BioCryst expects to use the net proceeds of this offering for general corporate purposes, including future clinical development of BCX7353, continued development of its second generation HAE compounds, including for other indications, and the advancement of its other preclinical rare disease programs.
J.P. Morgan Securities LLC is acting as sole book-running manager for the offering. Piper Jaffray & Co. is acting as lead manager and JMP Securities LLC is acting as co-manager for the offering. A shelf registration statement on Form S-3 relating to the shares of common stock described above has been previously filed with and declared effective by the U.S. Securities and Exchange Commission (SEC). This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. This offering is being made by means of a prospectus supplement and related prospectus.  A preliminary prospectus supplement relating to the offering has been filed with the SEC and is available on its website at www.sec.gov.  Copies of the final prospectus supplement, when available, and accompanying prospectus may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone: 1-866-803-9204. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases.  BioCryst currently has several ongoing development programs: BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema, and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is a potential treatment for filoviruses. Peramivir, a viral neuraminidase inhibitor, is approved for the treatment of influenza, in the U.S., Canada, Japan, Taiwan and Korea. Post-marketing commitment development activities are ongoing, as well as other activities to support additional peramivir regulatory approvals. This press release contains forward-looking statements, including statements regarding future results and achievements and the completion of this offering. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance, achievements, or outcomes to be materially different from any future results, performances, achievements, or outcomes expressed or implied by the forward-looking statements, including risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to this offering and other risks and uncertainties inherent in BioCryst's business. Please refer to the documents BioCryst files periodically with the SEC, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8‑K, which identify important factors that could cause the actual results to differ materially from those contained in BioCryst’s projections and forward-looking statements. BCRXW
CONTACT: Robert Bennett, BioCryst Pharmaceuticals, 1-919-859-7910 (investors & media)

Read more...
BioCryst Pharmaceuticals Commences Public Offering of Common Stock

RESEARCH TRIANGLE PARK, N.C., March 08, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it is offering to sell $45.0 million of its common stock in an underwritten public offering. As part of this offering, BioCryst intends to grant the underwriters a 30-day option to purchase up to an additional $6.75 million of its common stock. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
J.P. Morgan Securities LLC is acting as sole book-running manager for the proposed offering. All of the shares to be sold in the offering are being sold by BioCryst, with the proceeds to be used for general corporate purposes, including future clinical development of BCX7353, continued development of BioCryst’s second generation HAE compounds, including for other indications, and the advancement of its other preclinical rare disease programs. A shelf registration statement on Form S-3 relating to the shares of common stock described above has been previously filed with and declared effective by the U.S. Securities and Exchange Commission (SEC). This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. This offering is being made by means of a prospectus supplement and related prospectus. A preliminary prospectus supplement relating to the offering will be filed with the SEC and will be available on its website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone: 1-866-803-9204. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases.  BioCryst currently has several ongoing development programs: BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema, and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is a potential treatment for filoviruses. Peramivir, a viral neuraminidase inhibitor, is approved for the treatment of influenza, in the U.S., Canada, Japan, Taiwan and Korea. Post-marketing commitment development activities are ongoing, as well as other activities to support additional peramivir regulatory approvals. This press release contains forward-looking statements, including statements regarding future results and achievements and the completion of this offering. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance, achievements, or outcomes to be materially different from any future results, performances, achievements, or outcomes expressed or implied by the forward-looking statements, including risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to this offering and other risks and uncertainties inherent in BioCryst's business. Please refer to the documents BioCryst files periodically with the SEC, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause the actual results to differ materially from those contained in BioCryst's projections and forward-looking statements. BCRXW
CONTACT: Robert Bennett, BioCryst Pharmaceuticals, 1-919-859-7910 (investors & media)

Read more...

Ratios

vs
industry
vs
history
PB Ratio 301.90
BCRX's PB Ratio is ranked lower than
99% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. BCRX: 301.90 )
Ranked among companies with meaningful PB Ratio only.
BCRX' s PB Ratio Range Over the Past 10 Years
Min: 1.05  Med: 8.93 Max: 422.86
Current: 301.9
1.05
422.86
PS Ratio 17.76
BCRX's PS Ratio is ranked lower than
66% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. BCRX: 17.76 )
Ranked among companies with meaningful PS Ratio only.
BCRX' s PS Ratio Range Over the Past 10 Years
Min: 0.66  Med: 6.95 Max: 174.76
Current: 17.76
0.66
174.76
EV-to-EBIT -10.45
BCRX's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. BCRX: -10.45 )
Ranked among companies with meaningful EV-to-EBIT only.
BCRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -45.9  Med: -6 Max: 0.7
Current: -10.45
-45.9
0.7
EV-to-EBITDA -10.56
BCRX's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. BCRX: -10.56 )
Ranked among companies with meaningful EV-to-EBITDA only.
BCRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -54.1  Med: -6.2 Max: 0.7
Current: -10.56
-54.1
0.7
Current Ratio 1.23
BCRX's Current Ratio is ranked lower than
84% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. BCRX: 1.23 )
Ranked among companies with meaningful Current Ratio only.
BCRX' s Current Ratio Range Over the Past 10 Years
Min: 1.02  Med: 6.25 Max: 28.59
Current: 1.23
1.02
28.59
Quick Ratio 1.22
BCRX's Quick Ratio is ranked lower than
81% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. BCRX: 1.22 )
Ranked among companies with meaningful Quick Ratio only.
BCRX' s Quick Ratio Range Over the Past 10 Years
Min: 1  Med: 6.25 Max: 28.59
Current: 1.22
1
28.59
Days Inventory 222.92
BCRX's Days Inventory is ranked lower than
75% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. BCRX: 222.92 )
Ranked among companies with meaningful Days Inventory only.
BCRX' s Days Inventory Range Over the Past 10 Years
Min: 142.81  Med: 307.94 Max: 15234.51
Current: 222.92
142.81
15234.51
Days Sales Outstanding 121.44
BCRX's Days Sales Outstanding is ranked lower than
78% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. BCRX: 121.44 )
Ranked among companies with meaningful Days Sales Outstanding only.
BCRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.54  Med: 131.08 Max: 200.48
Current: 121.44
44.54
200.48
Days Payable 577.32
BCRX's Days Payable is ranked higher than
95% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. BCRX: 577.32 )
Ranked among companies with meaningful Days Payable only.
BCRX' s Days Payable Range Over the Past 10 Years
Min: 577.32  Med: 8523.65 Max: 34806.57
Current: 577.32
577.32
34806.57

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -7.70
BCRX's 3-Year Average Share Buyback Ratio is ranked higher than
63% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. BCRX: -7.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BCRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -20.4  Med: -8.9 Max: -0.6
Current: -7.7
-20.4
-0.6

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 301.90
BCRX's Price-to-Tangible-Book is ranked lower than
99% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. BCRX: 301.90 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BCRX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.42  Med: 4.32 Max: 301.9
Current: 301.9
0.42
301.9
Price-to-Median-PS-Value 2.56
BCRX's Price-to-Median-PS-Value is ranked lower than
90% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. BCRX: 2.56 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BCRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.13  Med: 3.45 Max: 418.75
Current: 2.56
0.13
418.75
Earnings Yield (Greenblatt) % -9.57
BCRX's Earnings Yield (Greenblatt) % is ranked lower than
53% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. BCRX: -9.57 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BCRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -9.57  Med: 487.1 Max: 1563.9
Current: -9.57
-9.57
1563.9

More Statistics

Revenue (TTM) (Mil) $26.35
EPS (TTM) $ -0.75
Beta3.00
Short Percentage of Float16.99%
52-Week Range $2.49 - 9.25
Shares Outstanding (Mil)80.38

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 33 33 13
EPS ($) -0.75 -0.64 -1.05
EPS without NRI ($) -0.75 -0.64 -1.05
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for BCRX

Headlines

Articles On GuruFocus.com
BioCryst to Announce First Quarter 2017 Financial Results May 4 Apr 24 2017 
BioCryst Expands Development of BCX7353 to Explore Treatment of Acute HAE Attacks Apr 12 2017 
BioCryst Announces Mundipharma Receives Approval for Mundesine® in Japan Apr 03 2017 
BioCryst Pharmaceuticals Prices Public Offering of Common Stock Mar 09 2017 
BioCryst Pharmaceuticals Commences Public Offering of Common Stock Mar 08 2017 
A Trump Presidency May Be Good for Biotech Dec 16 2016 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K/A) Jan 19 2011 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 

More From Other Websites
BioCryst to Announce First Quarter 2017 Financial Results May 4 Apr 24 2017
After announcing a $45M public offering, BioCryst to launch new trial Apr 13 2017
BioCryst Expands Development of BCX7353 to Explore Treatment of Acute HAE Attacks Apr 12 2017
BioCryst to receive royalties from cancer treatment approved in Japan Apr 04 2017
Stocks of companies with Raleigh-Durham area HQ make a comeback in March Apr 03 2017
BioCryst Announces Mundipharma Receives Approval for Mundesine® in Japan Apr 03 2017
BioCryst to Present at the 16th Annual Needham Healthcare Conference Mar 29 2017
Wait for the Pullback on BioCryst Pharmaceuticals Mar 20 2017
Don't Let Offerings Blindside Your Thesis Mar 19 2017
BioCryst Pharmaceuticals (BCRX) Shares March Higher, Can It Continue? Mar 15 2017
It’s time to vaccinate your investments against a deadly bird flu Mar 14 2017
BioCryst Pharmaceuticals Prices Public Offering of Common Stock Mar 09 2017
Biotech Premarket Movers: Spectrum, BioCryst, Curis Mar 09 2017
The Reason Behind BioCryst Pharmaceuticals, Inc.'s 12% Pop Higher Mar 08 2017
BioCryst Pharmaceuticals Commences Public Offering of Common Stock Mar 08 2017
Adamis (ADMP) Shows Strength: Stock Gains 6.7% in Session Mar 08 2017
BioCryst Pharmaceuticals, Inc. :BCRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017 Mar 07 2017
Biotech's Outlook Strengthens After President Trump's Speech: Today's Reports on Sarepta... Mar 03 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)